NASDAQ:NERV Minerva Neurosciences (NERV) Stock Forecast, Price & News $6.97 +0.07 (+1.01%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$6.97▼$6.9750-Day Range$6.90▼$10.5252-Week Range$1.26▼$14.70Volume620 shsAverage Volume401,982 shsMarket Capitalization$48.72 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Minerva Neurosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside59.4% Upside$11.00 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.63Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.94) to ($3.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector315th out of 969 stocksPharmaceutical Preparations Industry129th out of 454 stocks 3.0 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Minerva Neurosciences has a forecasted upside of 59.4% from its current price of $6.90.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.53% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 7.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.89. Previous Next 2.6 News and Social Media Coverage News SentimentMinerva Neurosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by Institutions55.11% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($3.94) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Minerva Neurosciences (NASDAQ:NERV) StockMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More NERV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NERV Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comContrasting Minerva Neurosciences (NASDAQ:NERV) and Atossa Therapeutics (NASDAQ:ATOS)August 23, 2023 | msn.comMinerva Neurosciences: There's Probably Time For One More RallyOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.August 1, 2023 | finance.yahoo.comMinerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesJune 28, 2023 | finanznachrichten.deMinerva Neurosciences, Inc: Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketJune 28, 2023 | benzinga.comMinerva Neurosciences shares are trading higher after the company announced a $20 million private placement priced at a premium to the market.June 28, 2023 | marketwatch.comMinerva Neurosciences Shares Jump Premarket After Private PlacementJune 28, 2023 | msn.comWhy Minerva Neurosciences Stock Is Shooting Higher TodayOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.June 28, 2023 | finance.yahoo.comMinerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketJune 9, 2023 | finance.yahoo.comHere's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock NowMay 19, 2023 | msn.comMinerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst AheadMay 18, 2023 | finance.yahoo.comWhat Makes Minerva Neurosciences (NERV) a New Buy StockMay 15, 2023 | benzinga.comMinerva Neurosciences Q1 2023 R&D Expenses $2.7M Vs $5M YoYMay 15, 2023 | finance.yahoo.comMinerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesMay 15, 2023 | msn.comMinerva Neurosciences GAAP EPS of -$1.31May 15, 2023 | finance.yahoo.comMinerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesMay 10, 2023 | marketwatch.comMinerva Neurosciences Gets FDA Confirmation for NDA for RoluperidoneMay 8, 2023 | finance.yahoo.comMinerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023May 3, 2023 | benzinga.comMinerva Neurosciences Stock (NASDAQ:NERV), Guidance and ForecastMay 3, 2023 | benzinga.comMinerva Neurosciences Stock (NASDAQ:NERV), Short Interest ReportMay 2, 2023 | markets.businessinsider.comMinerva Neurosciences (NERV) Receives a Hold from H.C. WainwrightMay 1, 2023 | marketwatch.comMinerva Neurosciences Shares Rise 25% FDA Files NDA for RoluperidoneMay 1, 2023 | finance.yahoo.comMinerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaApril 27, 2023 | marketwatch.comInsomnia Medication Market Forecast to 2030March 10, 2023 | finance.yahoo.comMinerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV) and Evolus (EOLS)See More Headlines Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Company Calendar Last Earnings8/01/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+59.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,110,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-45.87% Debt Debt-to-Equity RatioN/A Current Ratio27.37 Quick Ratio27.37 Sales & Book Value Annual Sales$41.18 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book Value($3.75) per share Price / Book-1.84Miscellaneous Outstanding Shares6,990,000Free Float6,545,000Market Cap$48.23 million OptionableOptionable Beta0.25 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Remy Luthringer Ph.D. (Age 62)Exec. Chairman & CEO Comp: $853.58kMr. Geoffrey Robin Race F.C.M.A. (Age 62)FCMA, M.B.A., MBA, Pres Comp: $628.46kMr. Frederick W. Ahlholm CPA (Age 57)CPA, Sr. VP, CFO & Sec. Comp: $567.49kMr. Joseph Reilly (Age 48)Sr. VP & COO Mr. William B. Boni (Age 71)VP of Investor Relations & Corp. Communications Prof. Michael Davidson M.D. (Age 73)Chief Medical Officer Dr. Ramana Kuchibhatla Ph.D.Sr. VP and Head of R&DMore ExecutivesKey CompetitorsRockwell MedicalNASDAQ:RMTIVistagen TherapeuticsNASDAQ:VTGNHookipa PharmaNASDAQ:HOOKRezoluteNASDAQ:RZLTDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 12,500 shares on 8/11/2023Ownership: 1.406%Geode Capital Management LLCBought 10,900 shares on 8/11/2023Ownership: 0.743%JPMorgan Chase & Co.Bought 4,514 shares on 8/11/2023Ownership: 0.065%Acadian Asset Management LLCSold 6,878 shares on 8/7/2023Ownership: 0.307%Virtu Financial LLCBought 20,993 shares on 7/27/2023Ownership: 0.377%View All Insider TransactionsView All Institutional Transactions NERV Stock - Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks. What is Minerva Neurosciences' stock price forecast for 2023? 2 equities research analysts have issued 12 month price targets for Minerva Neurosciences' shares. Their NERV share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 59.4% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts. How have NERV shares performed in 2023? Minerva Neurosciences' stock was trading at $1.59 at the beginning of the year. Since then, NERV stock has increased by 334.0% and is now trading at $6.90. View the best growth stocks for 2023 here. When is Minerva Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our NERV earnings forecast. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.68. When did Minerva Neurosciences' stock split? Minerva Neurosciences shares reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $6.90. How much money does Minerva Neurosciences make? Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $48.23 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-32,110,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com. This page (NASDAQ:NERV) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.